Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

NCT00437294 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

86

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Breast Cancer

Interventions

DRUG: enzastaurin
DRUG: placebo
DRUG: capecitabine

Sponsor

Eli Lilly and Company